| 1975 |
9 |
Established Nippon Chemical Research |
| |
10 |
Opened the Mikage Plant in Higashinada-ku, Kobe, Hyogo |
| 1976 |
12 |
Established a purification method for urokinase drug substance, a thrombolytic agent |
| 1977 |
4 |
Opened a research laboratory at the Mikage Plant |
| 1981 |
10 |
Relocated the research laboratory to Chuo-ku, Kobe, Hyogo |
| 1983 |
10 |
Received manufacturing approval for urokinase drug product and bulk solution |
| 1985 |
1 |
Received import approval for Growlum, a human growth hormone product |
| |
7 |
Opened the Tokyo Office in Shibuya-ku, Tokyo |
| 1986 |
6 |
Opened the Seishin Plant in Nishi-ku, Kobe, Hyogo (Seishin Industrial Park) |
| |
12 |
Relocated the research laboratory to a site adjacent to the Seishin Plant |
| 1992 |
10 |
Registered as an over-the-counter stock with the Japan Securities Dealers Association |
| 1993 |
4 |
Received manufacturing approval for GROWJECT™ Injection 4IU, a recombinant human growth hormone product |
| |
6 |
Relocated headquarters to Kasuga-cho, Ashiya, Hyogo (current location) |
| |
9 |
Launched TWINJECTOR® EZ, a needle-free pressure injector for GROWJECT™ |
| |
10 |
Relocated the research laboratory to Nishi-ku, Kobe, Hyogo (Kobe High-Tech Park) |
| 1994 |
3 |
Received manufacturing approval for Ulinastatin Bulk Solution “JCR,” a protease inhibitor drug substance |
| |
6 |
Opened the Seishin South Plant in Kobe High-Tech Park |
| 1995 |
3 |
Listed on the Second Section of the Osaka Securities Exchange |
| |
6 |
Established JCR Biopharmaceuticals, Inc. in the United States |
| |
8 |
Established Jiexi Pharmaceutical Co., Ltd. in China through a joint venture with Beijing Shanhe Medical & Health Development Co., Ltd., wholly owned by Beijing Hospital |
| 1996 |
11 |
Began importing and marketing the KONYJECTOR® Pen, an injection aid for GROWJECT™ |
| 1997 |
2 |
Established Family Health Rental Co., Ltd., a medical device sales company, in Chuo-ku, Kobe, Hyogo |
| 1999 |
1 |
Entered into a marketing alliance with Sumitomo Pharmaceuticals Co., Ltd. (now Sumitomo Pharma Co., Ltd.) for GROWJECT™ Injection 4IU |
| |
4 |
Assumed manufacturing approval for Leukoprol®, a treatment for leukopenia, from Morinaga Milk Industry Co., Ltd. |
| |
10 |
Received manufacturing approval for GROWJECT™ Injection 24IU and GROWJECT™ BC24 |
| |
12 |
Received approval for an additional indication for GROWJECT™ Injection 4IU for short stature in Turner syndrome without closed epiphyses |
| 2000 |
5 |
Opened the Kobe Plant in Kobe High-Tech Park |
| |
7 |
Launched GROWJECT™ Injection 1.33mg, GROWJECT™ Injection 8mg, GROWJECT™ BC8mg, and the GROWJECT™ Pen injector |
| |
10 |
Established Chromatec Co., Ltd., a distributor of research and medical equipment, in Nishinomiya, Hyogo |
| 2001 |
9 |
Launched GROWJECT™ Pen 0.1mg, a pen injector with 0.1 mg increments reflecting revised product specifications |
| 2004 |
8 |
Launched TWINJECTOR® EZ II, a needle-free pressure injector for GROWJECT™ |
| 2005 |
4 |
Opened the Clinical Trial Product Manufacturing Center (now Murotani Plant) in Kobe High-Tech Park |
| |
9 |
Launched the BD PenJector™ 2, an improved injector for GROWJECT™ |
| 2006 |
6 |
Began marketing imported paclitaxel drug substance, an anticancer agent, to Nippon Kayaku Co., Ltd. |
| |
10 |
Launched the GROWJECTER®, an electric injector for GROWJECT™ |
| 2008 |
4 |
Opened the Murotani Plant in Kobe High-Tech Park, reorganized from the Clinical Trial Product Manufacturing Center |
| 2009 |
7 |
Received approval for an additional indication for GROWJECT™ for adult growth hormone deficiency |
| |
7 |
Opened the Kobe Nishi Plant in Kobe High-Tech Park as a manufacturing facility for human mesenchymal stem cells |
| |
8 |
Launched the BD PenJector™ 3, the successor to the BD PenJector™ 2 injector for GROWJECT™ |
| 2010 |
5 |
Launched Epoetin Alfa BS Injection “JCR,” Japan’s first biosimilar for the treatment of renal anemia |
| 2011 |
3 |
Listed on the Second Section of the Tokyo Stock Exchange |
| |
10 |
Established JCR Engineering Co., Ltd. in Kobe High-Tech Park to manage pharmaceutical manufacturing facilities, equipment, and instruments |
| 2012 |
7 |
Launched GROWJECTER® 2, the successor to the GROWJECTER® electric injector for GROWJECT™ |
| 2012 |
8 |
JCR receives an Approval for Expanded Indication of Growject™ in Short Stature due toSmall-for-Gestational Age (SGA) |
| 2013 |
5 |
Opened the Kobe API Plant in Nishi-ku, Kobe, Hyogo Prefecture (Kobe High-Tech Park) |
| |
11 |
Listed on the First Section of the Tokyo Stock Exchange |
| 2014 |
1 |
Renamed to JCR Pharmaceuticals Co., Ltd. |
| 2015 |
8 |
Opened the Kobe Logistics Center in Nishi-ku, Kobe, Hyogo Prefecture (Kobe High-Tech Park) |
| |
11 |
Established JCR INTERNATIONAL SA, a market research company, in Switzerland |
| 2016 |
2 |
Launched TEMCELL™ HS Inj., Japan’s first allogeneic regenerative medicine product. |
| |
4 |
Opened a Clinical Trial Drug Manufacturing Center and a Cell Processing Center within the research institute premises |
| |
6 |
Obtained manufacturing and marketing approval for the liquid formulation of the recombinant human growth hormone product “Growject™ |
| 2017 |
1 |
Launched “Growjecter® L,” an electric injection device dedicated to the liquid formulation of “Growject™ |
| 2018 |
1 |
Established JCR USA, Inc. in the United States to oversee clinical development |
| |
11 |
Launched Agalsidase Beta BS Intravenous Infusion “JCR,” the Company’s first enzyme replacement therapy for lysosomal storage disorders |
| |
11 |
Launched the long-acting erythropoiesis-stimulating agent “Darbepoetin Alfa BS Injection ‘JCR’ |
| 2020 |
4 |
Acquired all shares of ArmaGen, Inc., a U.S. biopharmaceutical R&D company |
| |
4 |
Absorbed and merged Family Health Rental Co., Ltd. |
| |
9 |
JCR DO BRASIL FARMACÊUTICOS IMPORTAÇÃO E EXPORTAÇÃO LTDA. commenced operations |
| |
10 |
Co-developed Meron Diary®, a smartphone app for the GROWJECTER® L injector for GROWJECT™, with PHC Corporation |
| |
12 |
Entered into a manufacturing services agreement with AstraZeneca K.K. for domestic drug substance production of the COVID-19 vaccine AZD1222 |
| 2021 |
1 |
Opened the Bioresearch Center in Kobe High-Tech Park |
| |
5 |
Launched IZCARGO™ for I.V. Infusion 10mg in Japan |
| 2022 |
2 |
IZCARGO™ for Intravenous Infusion received the New Treatment Award at WORLDSymposium™ 2022 |
| |
4 |
Moved from the First Section to the Prime Market of the Tokyo Stock Exchange following the market restructuring |
| |
4 |
Transferred marketing of Agalsidase Beta BS Intravenous Infusion “JCR” to Sumitomo Pharma Co., Ltd. |
| |
8 |
Established JCR Luxembourg S.A. as a European base for global distribution management |
| |
9 |
Established JCR Europe B.V. in the Netherlands to oversee clinical development |
| |
9 |
Selected for the Ministry of Economy, Trade and Industry’s program to strengthen biopharmaceutical manufacturing infrastructure for vaccine production |
| |
10 |
Established AlliedCel Corporation with Sysmex Corporation to conduct R&D on regenerative medicine products |
| |
10 |
Acquired shares of Mycenax Biotech Inc., a Taiwanese biopharmaceutical CDMO |
| |
11 |
Opened the Kobe Science Park Center in Kobe Science Park |
| 2023 |
6 |
Received approval for an additional indication for GROWJECT™ for short stature associated with SHOX deficiency without closed epiphyses |
| |
9 |
Launched GROWJECTER® Duo, a new electric injector for GROWJECT™, co-developed with PHC Corporation |
| 2025 |
5 |
Revised the corporate philosophy and core values |
| |
9 |
Adopted the corporate slogan “Life is Rare” |
